Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the ...

Pharmaceutical giant Pfizer Inc. (PFE) on Monday announced that it is ending the development of its experimental weight loss ...

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.

Liver damage associated with MASH can lead ... and retatrutide, a GLP-1/GIP/glucagon receptor agonist. Research suggests both therapies may prove beneficial in patients with MASH.

After reviewing all the data and considering input from regulators, Pfizer decided to discontinue the danuglipron program.

DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading ... DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss ...

MetaVia (MTVA) announced positive results from the 4-week multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, ...

Pfizer (PFE) announced the decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was ...